Despite a below expectations Q4, at least partly due to increased sickness-related absences, we see ...
Pihlajalinna’s profitability challenges continued to be way worse in Q4 than estimated.
Göteborgsbaserade investmentbolaget Northern CapSek Ventures AB (”CapSek”) portföljbolag Klash Studi...
Redeye provides an update in relation to Optomed’s Q4 2022 report.
There will be two alternative IgAN therapies on the US market by the last week of February 2023 as t...
Redeye believes Transtema’s settlement agreement with GlobalConnect is reasonable.
Redeye retains its positive view of Speqta despite slightly lowering its forecast and Base Case.
Q4 NOI beat of 10% filtering through Highest occupancy in the Swedish RE sector P/NAV at ~0.
Smart High Tech publicerade den 17 februari 2023 bolagets delårsrapport för det fjärde kvartalet 202...
Gynnas av en diversifierad affär Clemondo avslutade det händelserika året 2022 med en omsättning på ...
Redeye notes a continuous customer base growth (+72%), and we are encouraged by the company’s FDA ap...
Redeye comments on Jondetech’s excersice of warrants, which was subscribed to almost 55% and bringin...
Redeye updates its estimates and fair value range following Tessin’s Q4 report.
Redeye provides a comment on Northbaze's 2022 preview
Redeye updates its fair value range following Alelion’s Q4 report, which was weaker than expected.
During the fourth quarter, Ngenic entered several partnership agreements, received a breakthrough or...
Stockwik delivered a somewhat soft Q4 with a sales growth of 24% y/y, while EBITA declined 2% y/y, b...
Ferronordic presented a higher dividend and 47% stronger sales for Q4 than we forecast, due to marke...
Finding a new level of growth post COVID-19 Impressive profitability in Q4 Low churn confirmed, as e...
EcoRub publicerade den 17 februari 2023 bolagets helårsrapport för år 2022 samt det fjärde kvartalet...
